Salsalate Improves Glycemia and Inflammatory Parameters in Obese Young Adults
- 1 February 2008
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 31 (2), 289-294
- https://doi.org/10.2337/dc07-1338
Abstract
OBJECTIVE—Sedentary lifestyle and a western diet promote subacute-chronic inflammation, obesity, and subsequently dysglycemia. The aim of the current study was to evaluate the efficacy of the anti-inflammatory drug salsalate to improve glycemia by reducing systemic inflammation in obese adults at risk for the development of type 2 diabetes. RESEARCH DESIGN AND METHODS—In a double-masked, placebo controlled trial, we evaluated 20 obese nondiabetic adults at baseline and after 1 month of salsalate or placebo. RESULTS—Compared with placebo, salsalate reduced fasting glucose 13% (P < 0.002), glycemic response after an oral glucose challenge 20% (P < 0.004), and glycated albumin 17% (P < 0.0003). Although insulin levels were unchanged, fasting and oral glucose tolerance test C-peptide levels decreased in the salsalate-treated subjects compared with placebo (P < 0.03), consistent with improved insulin sensitivity and a known effect of salicylates to inhibit insulin clearance. Adiponectin increased 57% after salsalate compared with placebo (P < 0.003). Additionally, within the group of salsalate-treated subjects, circulating levels of C-reactive protein were reduced by 34% (P < 0.05). CONCLUSIONS—This proof-of-principle study demonstrates that salsalate reduces glycemia and may improve inflammatory cardiovascular risk indexes in overweight individuals. These data support the hypothesis that subacute-chronic inflammation contributes to the pathogenesis of obesity-related dysglycemia and that targeting inflammation may provide a therapeutic route for diabetes prevention.Keywords
This publication has 43 references indexed in Scilit:
- The dual function of hepatic SOCS3 in insulin resistance in vivoGenes to Cells, 2007
- Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialThe Lancet, 2006
- Inflammation and insulin resistanceJCI Insight, 2006
- Metformin Inhibits Proinflammatory Responses and Nuclear Factor-κB in Human Vascular Wall CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseThe New England Journal of Medicine, 2005
- Prevention of fat-induced insulin resistance by salicylateJCI Insight, 2001
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)Jama-Journal Of The American Medical Association, 2001
- Inhibition of NF-κB by Sodium Salicylate and AspirinScience, 1994
- Salicylates as Hypoglycemic AgentsDiabetes Care, 1982
- Lack of platelet effect with the aspirin analog, salsalateArthritis & Rheumatism, 1980